Possible Bearish Signals With LeMaitre Vascular Insiders Disposing Stock
Possible Bearish Signals With LeMaitre Vascular Insiders Disposing Stock
In the last year, many LeMaitre Vascular, Inc. (NASDAQ:LMAT) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, if numerous insiders are selling, shareholders should investigate more.
在過去的一年中,許多勒梅特微管醫療公司(納斯達克:LMAT)的內部人士出售了大量股份,這可能引起了股東的注意。當分析內部交易時,了解內部人士是買入還是賣出通常更有價值,因爲後者傳遞了一個模糊的信息。然而,如果有許多內部人士賣出股票,股東應該進行更多的調查。
While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.
雖然在長期投資方面內部交易並非最重要的事情,但完全忽略內部交易是愚蠢的。
LeMaitre Vascular Insider Transactions Over The Last Year
勒梅特微管醫療公司近一年的內部交易情況
The Chairman & CEO, George LeMaitre, made the biggest insider sale in the last 12 months. That single transaction was for US$7.5m worth of shares at a price of US$75.94 each. That means that an insider was selling shares at slightly below the current price (US$90.00). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was only 4.6% of George LeMaitre's holding.
董事長兼首席執行官George LeMaitre在過去12個月中進行了最大規模的內部交易。那次交易的股票價值爲750萬美元,每股價格爲75.94美元。這意味着內部人士在略低於當前價格(90.00美元)時出售股票。一般而言,當內部人士以低於當前價格出售股票時,我們認爲這是令人沮喪的,因爲這意味着他們對較低估值感到滿意。雖然內部人士的賣出並不是一個積極的信號,但我們不能確定它是否意味着內部人士認爲這些股票已經完全估值,所以這只是一個弱信號。值得注意的是,這次交易僅佔George LeMaitre持股的4.6%。
Insiders in LeMaitre Vascular didn't buy any shares in the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
勒梅特微管醫療公司的內部人士在過去一年中沒有購買任何股票。您可以在下面的圖表中查看過去一年內的內部交易(按公司和個人分類)。如果您想知道確切的賣家、交易金額和交易時間,請直接點擊下面的圖表!
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
如果你喜歡購買內部人員正在購買而不是銷售的股票,那麼你可能會喜歡這份免費的公司列表。(提示:它們中的大部分都被忽視了。)
Does LeMaitre Vascular Boast High Insider Ownership?
勒梅特微管醫療是否擁有高比例內部持股?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It's great to see that LeMaitre Vascular insiders own 8.8% of the company, worth about US$177m. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
審視一家公司內部股東的總持股可以幫助你判斷他們是否與普通股東利益保持一致。通常情況下,內部持股比例越高,內部人士就越有動力長期發展公司。很高興看到勒梅特微管醫療內部人士擁有公司的8.8%,價值約17700萬美元。大多數股東會很高興看到這種內部持股,因爲它意味着管理層的激勵與其他股東利益保持一致。
So What Does This Data Suggest About LeMaitre Vascular Insiders?
這些數據對勒梅特微管醫療內部人士有何暗示?
The fact that there have been no LeMaitre Vascular insider transactions recently certainly doesn't bother us. It's great to see high levels of insider ownership, but looking back over the last year, we don't gain confidence from the LeMaitre Vascular insiders selling. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
最近勒梅特微管醫療內部人士沒有進行任何交易,並不讓我們感到困擾。很高興看到內部持股比例高,但回顧過去一年,勒梅特微管醫療內部人士的賣出並沒有增加我們的信心。如果你像我一樣,你可能會想考慮這家公司是會增長還是會縮小。幸運的是,你可以查看這份免費報告,其中顯示了對其未來的分析師預測。
But note: LeMaitre Vascular may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但請注意:勒梅特微管醫療可能不是最好的股票買入選擇。因此,請查看這份免費的有高roe和低債務的有趣公司名單。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。